2024 Agenda
*All times are in MST
Sep
Fri 13
Meeting registration
Meeting objectives & introduction to Day 1
Naval Daver
Session 1: Updates on established therapies in AML – Part 1
Chairs: Andrew Wei & Eytan Stein
- IC+VEN in newly diagnosed fit AML – current status and patient selection: Tapan Kadia
- Optimizing transplant outcomes in AML and role of maintenance post ASCT: Charles Craddock
- Role and optimal maintenance strategies in AML patients not going to ASCT: Maximilian Stahl
- CPX updates & new data: Tara Lin
Panel discussion
Session 2: Translational and lab developments and applications in AML
Chairs: Ravi Majeti & Uma Borate
- Antigen targets and novel CAR-T strategies: Ravi Majeti
- Potential for early intervention in CHIP and CCUS: Uma Borate
- Designing and applying a FLT3 like signature in AML: Adrián Mosquera Orgueira
- Ancestry-inclusive consideration of AML genomics: Ann-Kathrin Eisfeld
- Approaches to leverage single-cell sequencing in understanding AML biology and response to therapy: Koichi Takahashi
Panel discussion
Day 1 conclusions
Welcome reception
Sep
Sat 14
Introduction to Day 2
Naval Daver
Session 3: Updates on established therapies in AML – Part 2
Chairs: Naval Daver & Charles Craddock
- Optimal approach to treatment of secondary/therapy related AML: Jorge Cortes
- How does IDHm impact frontline treatment of AML: Courtney DiNardo
- Frontline approaches for FLT3-mutant AML: Naval Daver
- Current approaches and challenges for relapsed FLT3-mutant AML: Alexander Perl
Panel discussion
Session 4: International trials group
Chairs: Courtney DiNardo & Charles Craddock
- MDACC: Naval Daver
- UK & European trials: Charles Craddock
- French trials: Stéphane de Botton
- myeloMATCH: Richard Little
Panel discussion
Break
Session 5: Less intensive therapy should be used in all older newly diagnosed AML patients even if fit for intensive chemotherapy
Chairs: Mark Levis & Jessica Altman
Pro: Eunice Wang & Tapan Kadia
Con: Harry Erba & Stéphane de Botton
Lunch
Session 6: New frontiers in MRD for AML clinical practice
Chairs: Stéphane de Botton & Gail Roboz
- Single-cell sequencing and clinical applicability in detection and therapy of AML: Catherine Smith
- MRD as a clinical endpoint in clinical trials: Nicholas Short
- Applying MRD techniques in FLT3-mutated AML – are we able to use MRD as an endpoint?: Christopher Hourigan
Panel discussion
Session 7: BPDCN & MDS/MPN + CMML
Chairs: Marina Konopleva & TBC
- Updates in diagnosis, pathogenesis, and future directions in BPDCN: Marina Konopleva
- VEXAS syndrome: Emma Groarke
- Future targets and trial progress in CMML: Guillermo Montalbán Bravo
- AP/BP MPN to post-MPN AML: Anand Patel
Panel discussion
Break
Session 8: Transplant and immunotherapies in AML
Chairs: Charles Craddock & Roland Walter
- Which patients with AML in MRD+ remission should be transplanted?: Roland Walter
- Early phase CAR-T and NK cell trials for R/R AML and MDS: Nelli Bejanyan
- NK cell-based therapies in AML: Jeffrey Miller
Panel discussion
Session 9: Special session on regulatory endpoints in AML
Chairs: Naval Daver & Courtney DiNardo
- The FDA’s perspective on regulatory endpoints in AML: Kelly Norsworthy
- A clinical investigator’s perspective on drug development and endpoints: Gail Roboz
Panel discussion
Day 2 conclusions
Faculty dinner
Sep
Sun 15
Introduction to Day 3
Session 10: Menin inhibition
Chairs: Naval Daver & TBC
- Single-agent menin inhibitors – efficacy, biomarkers and resistance: Eunice Wang
- Updates on menin inhibitor-based combination in AML: Ghayas Issa
- Frontline triplets with menin inhibitors in newly diagnosed AML – ready for primetime?: Joshua Zeidner
Panel discussion
Session 11: Novel targets, combinations and treatments in AML part 1 – new AML therapies and limitations
Chairs: Richard Stone & Marina Konopleva
- Overcoming resistance to venetoclax-based therapies in AML: Marina Konopleva
- Promising combination options in AZA/VEN for R/R AML: Thomas Cluzeau
Panel discussion
Break
Session 12: Novel targets, combinations and treatments in AML part 2
Chairs: Tapan Kadia & Eunice Wang
- TP53 treatment strategies in AML – how do we crack this nut?: David Sallman
- Tuspetinib for relapsed or refractory AML: Gabriel Mannis
- Protein degradation as an emerging therapy in AML/leukemia: Geoffrey Uy
Panel discussion
Session 13: Novel targets, combinations and treatments in AML Part 3
Chairs: Farhad Ravandi & Catherine Smith
- Optimal use of OGM and RNA-translocation panel in frontline AML: Sanam Loghavi
- Novel ADCs in AML – how best to incorporate and use them: Farhad Ravandi
- Leveraging STING for therapeutic benefit in AML: Andrew Wei
Panel discussion
Day 3 conclusions & closing remarks
Followed by lunch